Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
NIHR Bioresource Rare Diseases, |
RCV000851583 | SCV000899299 | likely pathogenic | Coagulation factor deficiency syndrome | 2019-02-01 | criteria provided, single submitter | research | |
ISTH- |
RCV002222013 | SCV002499624 | likely pathogenic | Hereditary factor XI deficiency disease | criteria provided, single submitter | clinical testing | ||
Women's Health and Genetics/Laboratory Corporation of America, |
RCV002222013 | SCV005395273 | pathogenic | Hereditary factor XI deficiency disease | 2024-09-20 | criteria provided, single submitter | clinical testing | Variant summary: F11 c.1207G>A (p.Val403Met) results in a conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 251482 control chromosomes (gnomAD). c.1207G>A has been reported in the literature in a homozygous individual affected with Hereditary factor XI deficiency disease (Dai_2011), as well as 2 heterozygous individuals reported to have a coagulation disorder (Downes_2019). These data indicate that the variant is likely to be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function, finding that the variant resulted in sharply decreased extracellular secretion (5.7% of wild type antigen level), as well as inhibiting secretion of heterodimers of the mutant and wild type protein (Dai_2011), suggesting a possible dominant negative effect. The following publications have been ascertained in the context of this evaluation (PMID: 21457405, 31064749). ClinVar contains an entry for this variant (Variation ID: 68173). Based on the evidence outlined above, the variant was classified as pathogenic. |
Uni |
RCV000059005 | SCV000090526 | not provided | not provided | no assertion provided | not provided |